Ran Nussbaum - 19 May 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role: Director
Signature: /s/ Neil S. Belloff, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 19 May 2021
Net transactions value: $0
Form type: 4
Filing time: 20 May 2021, 16:10:50 UTC
Previous filing: 17 May 2021
Next filing: 03 Jun 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELOX	Stock Option (Right to Buy)	Award	$0	+20,000		$0.000000	20,000	19 May 2021	Common Stock	20,000	$1.48	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.
F2	The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner.

Content

The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner.